Clinical Trial Update: Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study [Phase 3]

View source ↗

Summary

A Phase 3 randomized, placebo-controlled trial of teprotumumab infusions in Graves' orbitopathy (thyroid eye disease) completed with results posted in 2020, dem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Orbitopathy
• Thyroid Eye Disease

Drugs mentioned

• TEPEZZA (teprotumumab)

Snippet

Sponsor: Amgen | Conditions: Thyroid Eye Disease, Graves' Orbitopathy | Phase 3 | Status: COMPLETED | Results posted: 2020-03-10